Positive OASIS extension results: 67% of wet AMD patients went ≥6 months without retreatment; cash $48.3M

Clearside Biomedical, Inc.

67% of extension participants (8/12) went ≥6 months without additional treatment; 50% went >6 months.
Treatment burden reduced 77-85% vs. average monthly injections prior to CLS-AX administration.
No serious adverse events, inflammation, vasculitis, or vascular occlusion; excellent safety profile.
Planned initiation of Phase 2b ODYSSEY trial in Q1 2023 with primary endpoint readout mid-2024.
Preliminary unaudited cash and cash equivalents of $48.3M as of December 31, 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.